In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genomics Collaborative Inc.

Latest From Genomics Collaborative Inc.

Deal Statistics Quarterly, Q2 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.

BioPharmaceutical Medical Device

Fibromyalgia: The Newest Psychiatric Market

Cypress Bioscience has reinvented itself in the past year to focus on the development of drugs for fibromyalgia syndrome, a mysterious disease characterized by pain and sleeplessness in the absence of measurable pathophysiological features.

BioPharmaceutical Strategy


Despite the in silico research ideals of many genomicists, no one has yet found a way around the basic requirement for using human tissue in gene expression studies-a broad array of it, well characterized, from healthy and diseased patients, and from world populations at large. That's why start-ups, drug discovery firms and others are creating a new resource: biorepositories--banks of tissue samples and data to serve the diagnostic, pharmaceutical and tissue engineering industries. As providers of services and products to research-based companies, these companies believe they are operating in a market that ranges from $500 million to $5 billion.

BioPharmaceutical Business Strategies

Genomics Collaborative Inc.

Genomics Collaborative Inc. looks like two distinct businesses: a functional genomics company in Cambridge, MA and a clinical research organization in Blue Bell, Pennsylvania. But they are really two halves of a single drug discovery company, says Michael Pellini, MD, CEO; one that possesses the analytical tools for genetic association studies and biological analysis and the patient biological samples to back them up.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics